The Novozymes stock

    The Novozymes stock had a good year in 2013, gaining 44%. In April, 5.3 million B shares were canceled.

    The Novozymes stock is listed on Nasdaq OMX Copenhagen and included in the OMX Copenhagen 20 index (OMXC20CAP). The stock is listed under ticker code NZYM B and ISIN DK0060336014. Novozymes is registered with the Danish Business Authority under 10 00 71 27.

    Stock performance

    Novozymes’ stock (DKK) 2013 2012
    Share price, year-end 228.9 159.2
    Total market value, year-end (billion)* 73.2 51.7
    Earnings per share, diluted 6.93 6.33
    Dividend per share 2.50** 2.20
    * All A and B shares multiplied by the price of the B share.
    ** Proposed.

     

    ###GRAF: Indexed share performance###

    Novozymes' share price increased by 44% during the year. In comparison, the OMXC20CAP gained 32%, the MSCI Pan Europe Index gained 16%, and the Dow Jones Sustainability World Index was up 20%.

    The average daily trading volume of Novozymes' stock in 2013 was 424,988 shares, or DKK 84 million, making it the seventh most actively traded company on Nasdaq OMX Copenhagen, the same rank as in 2012. At year-end, the total market value of Novozymes' B shares was DKK 60.9 billion, and the value of the nontraded A shares was DKK 12.3 billion, assuming the same value per share as for the B shares.

    Over the past five years, Novozymes' stock has generated a compound average annual return to shareholders of 22% (23% including dividends). This can be compared with a five-year compound average return without dividends of 20% for the OMXC20, 9% for the MSCI Pan Europe Index and 11% for the Dow Jones Sustainability World Index.

    As resolved at the Annual Shareholders’ Meeting in February 2013, 5.3 million B shares were canceled in a capital reduction on April 5, 2013.

    “In 2013, Novozymes was named as Biotechnology Industry Leader for the 12th time and awarded a Gold Class rating for 2012 performance in RobecoSAM's Sustainability Yearbook 2013.”

    ###GRAF: FIVE-YEAR Indexed share performance###

    Dividends

    The Board of Directors proposes that the Annual Shareholders' Meeting 2014 approve a dividend of DKK 2.50 per share for the 2013 financial year. This will result in an expected total dividend payment of approximately DKK 786 million, corresponding to a payout ratio of 35.7%.

    Stock buyback program in 2014

    As announced on December 10, 2013, in relation to the formation of The BioAg Alliance with Monsanto, Novozymes expects to initiate a new stock buyback program in 2014 worth up to DKK 2 billion.

    Distributions 2013 2012 2011 2010 2009
    Dividends (DKK million) 786* 687 599 504 358
    Stock buybacks (DKK million) 0 832 400 0 0
    Total (DKK million) 786* 1,519 999 504 358
    Net profit (DKK million) 2,201 2,016 1,828 1,614 1,194
    Payout ratio (%)  35.7* 34.0 32.8 31.2 30.0
    Number of shares outstanding,
    year-end (million)
    314 312 315 315 311
    Dividend per share (DKK) 2.50* 2.20 1.90 1.60 1.15
    * Proposed.

     

    Dividend dates 2014

     
    Resolution adopted at the Annual Shareholders' Meeting February 26
    Last day of trading with right to dividend for 2013 February 26
    First day of trading without right to dividend for 2013 February 27
    Disbursement of dividend March 4

     

    Equity analysts

    The following companies have analysts covering Novozymes’ stock:

    ABG Sundal Collier   Jefferies & Company 
    Alm. Brand Markets   J.P. Morgan
    Carnegie   Jyske Bank
    CA Cheuvreux Nordic   Kempen & Co.
    Citi   Nordea Markets
    Credit Suisse   Nykredit Markets 
    Danske Markets   SEB Enskilda Equities
    DnB NOR Markets   Standard & Poor's
    Goldman Sachs   Sydbank
    Handelsbanken Capital Markets   UBS

     

    Sustainability ratings

    Providing information on sustainability performance to analysts, rating agencies and asset managers is an important element of Novozymes' interaction with shareholders. We continuously seek to improve our sustainability reporting and processes, and value this interaction highly. In 2013, Novozymes was:

    • Reconfirmed as a member of the Dow Jones Sustainability World Index and the Dow Jones Sustainability STOXX Index, named as Biotechnology Industry Leader for the 12th time and awarded a Gold Class rating for 2012 performance in RobecoSAM's Sustainability Yearbook 2013
    • Ranked third in the Carbon Disclosure Project's Nordic Carbon Disclosure Leadership Index 2013 with a score of 99 out of 100
    • Reconfirmed as having PRIME status by Oekom Research for being among the leaders in the pharmaceuticals & biotechnology industry
    • Reconfirmed as one of The Global 100 Most Sustainable Corporations in the World
    • Reconfirmed as a member of the ET Global 300 Carbon Index
    • Reconfirmed as a member company of the FTSE4Good Index

     Novozymes' common stock

       
    A stock B stock Total
           
    Common stock (DKK)* 107,487,200 531,912,800 639,400,000
    Number of shares 53,743,600 265,956,400 319,700,000
    Number of votes 1,074,872,000 531,912,800 1,606,784,800
    Voting rights (%) 66.9 33.1 100
     * Common stock equals 319,700,000 shares with a nominal value of DKK 2 per share

    Shareholders

    Novozymes' common stock consists of two types: A shares and B shares, both with a nominal value of DKK 2 per share. All A stock is held by Novo A/S, and an A share carries 10 times as many votes as a B share.

    ###GRAPH: Shareholder distribution of B common stock###

    At the end of 2013, Novo A/S held 25.9% of the total common stock and, through its holding of the A stock and a proportion of the B stock (29,131,400 shares), controlled 70.5% of the votes. Novo A/S is wholly owned by the Novo Nordisk Foundation, and Novozymes is therefore included in the consolidated financial statements of the Novo Nordisk Foundation. Novo A/S is domiciled in Hellerup, Denmark.

    At year-end, Novozymes had roughly 49,000 shareholders, of whom 99% were private shareholders in Denmark. Twenty institutional investors, including Novo A/S, owned approximately 60% of the B shares. Around 65% of the B shares were held outside Denmark.

    Novozymes held 2.1% of the B stock, equivalent to 1.7% of the total common stock.

    Besides Novo A/S, only one shareholder, Baillie Gifford & Co., held more than 5% of Novozymes' common stock on December 31, 2013.

    “The average daily trading volume of Novozymes' stock in 2013 was 424,988 shares, or DKK 84 million, making it the seventh most actively traded company on Nasdaq OMX Copenhagen.”

    Financial calendar

    Group financial statement for 2013 Jan. 21, 2014
    Annual Shareholders' Meeting 2014 Feb. 26, 2014
    Interim report for the first 3 months of 2014 April 24, 2014
    Interim report for the first half of 2014 Aug. 14, 2014
    Interim report for the first 9 months of 2014 Oct. 23, 2014
    Group financial statement for 2014 Jan. 20, 2015

    Contact Investor Relations

    Visit our Investor site at www.novozymes.com for investor relations guidelines, presentations, tools and downloads, Group financial statements and other information for both private and institutional shareholders.

    If you have questions for Investor Relations, please contact:

    Thomas Steenbech Bomhoff
    Head of Investor Relations
    Tel.: +45 4446 1226
    Email: tsbm@novozymes.com

    Martin Riise
    Senior Investor Relations Manager, U.S.
    Tel.: +1 919 494 3483
    Email: mrsn@novozymes.com

    Klaus Sindahl
    Senior Investor Relations Manager, Europe
    Tel.: +45 4446 0134
    Email: ksdh@novozymes.com